Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
Provided By GlobeNewswire
Last update: May 15, 2025
– Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial –
– RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. patients with no approved treatments other than monthly IVIg –
Read more at globenewswire.com1.57
-0.13 (-7.65%)
Find more stocks in the Stock Screener
CABA Latest News and Analysis
17 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
17 days ago - ChartmillTop movers analysis in the middle of the day on 2025-06-11: top gainers and losers in today's session.Curious about what's happening in today's session? Check out the latest stock movements and price changes.
17 days ago - ChartmillWhich stocks are gapping on Wednesday?Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
